These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 9494557)

  • 1. Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model.
    Zagozdzon R; Stokłosa T; Gołab J; Giermasz A; Dabrowska A; Lasek W; Jakóbisiak M
    Anticancer Res; 1997; 17(6D):4493-8. PubMed ID: 9494557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
    Winkelhake JL; Stampfl S; Zimmerman RJ
    Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
    Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
    Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
    Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
    J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combined effect of TNF and anticancer chemotherapeutic agents on murine bladder tumor (MBT-2)].
    Ikemoto S; Iimori H; Nishimoto K; Hayahara N; Kamizuru M; Wada S; Hayahara M
    Hinyokika Kiyo; 1992 Mar; 38(3):285-9. PubMed ID: 1523983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice.
    Feleszko W; Lasek W; Gołab J; Jakóbisiak M
    Neoplasma; 1995; 42(2):69-74. PubMed ID: 7617079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells.
    Wu B; Shen RN; Wang WX; Broxmeyer HE; Lu L
    Stem Cells; 1993 Sep; 11(5):412-21. PubMed ID: 8241952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
    McIntosh JK; Mulé JJ; Merino MJ; Rosenberg SA
    Cancer Res; 1988 Jul; 48(14):4011-7. PubMed ID: 3260130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats.
    Ohno S; Strebel FR; Stephens LC; Siddik ZH; Makino M; Klostergaard J; Tomasovic SP; Khokhar AR; Bull JM
    Cancer Res; 1992 Aug; 52(15):4096-101. PubMed ID: 1638521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice.
    Dabrowska A; Giermasz A; Marczak M; Gołab J; Jakóbisiak M
    Anticancer Res; 2000; 20(1A):391-4. PubMed ID: 10769685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice.
    Lasek W; Golab J; Maśliński W; Switaj T; Bałkowiec EZ; Stokłosa T; Giermasz A; Malejczyk M; Jakóbisiak M
    Eur Cytokine Netw; 1999 Sep; 10(3):345-56. PubMed ID: 10477391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor alpha mediates the antitumor effect of combined interleukin-2 and whole body hyperthermia.
    Fritz KL; Koziol S; Fabian DF; Lefor AT
    J Surg Res; 1996 Jan; 60(1):55-60. PubMed ID: 8592432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells.
    Ghosh S; Maity P
    Int Immunopharmacol; 2007 Dec; 7(13):1598-608. PubMed ID: 17996669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo effects of purified recombinant human macrophage colony-stimulating factor in combination with local hyperthermia on tumor progression in B16a melanoma bearing mice.
    Lu L; Xiao M; Wu B; Wang WX; Yan WR; Broxmeyer HE; Shen RN
    Int J Hematol; 1993 Oct; 58(3):139-52. PubMed ID: 8148492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
    Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
    Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice.
    Dabrowska A; Giermasz A; Gołab J; Jakóbisiak M
    Neoplasma; 2001; 48(5):358-61. PubMed ID: 11845979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.